secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2025-09-29T23:59:59+00:00
Accession:  0001104659-25-094558
Event type: regulatory
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics completes FDA Type A meeting for ONS-5010 BLA; plans resubmission in 2025
--------------------------------------------------------------------------------

- Type A meeting with FDA discussed August 27, 2025 CRL for ONS-5010 BLA (bevacizumab for wet AMD).
- Company expects to resubmit BLA before end of calendar year 2025 after reviewing FDA feedback.
- CEO Bob Jahr stated productive discussion; written minutes still pending.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465925094558/0001104659-25-094558-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465925094558/tm2527376d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-094558

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer